SEATTLE--(BUSINESS WIRE)--Oisín Biotechnologies (Oisín), a privately held biotechnology company focused on mitigating the effects of age-related diseases, today announced the publication of preclinical data from its follistatin (FST) gene therapy program to mitigate muscle loss in an article titled “Safe and Effective Delivery of DNA and RNA Using Proteolipid Vehicles” in Cell.

西雅图——（商业新闻短讯）——Oisín Biotechnologies（Oisín）是一家专注于减轻与年龄有关的疾病影响的私营生物技术公司，今天宣布发布其卵泡抑素（FST）基因治疗计划的临床前数据，以减轻肌肉损失，文章标题为“使用蛋白脂质载体在细胞中安全有效地传递DNA和RNA”。

Scientists at Oisín, OncoSenX, the University of Alberta, Dalhousie University, and Aegis Life, Inc., contributed to the published research led by Entos® Pharmaceuticals, inventor of the FAST-PLV™ platform. The article is available from Cell online today and in print on September 19th..

Oisín，OncoSenX，阿尔伯塔大学，达尔豪西大学和Aegis Life，Inc.的科学家为FAST-PLV™平台的发明者Entos®Pharmaceuticals领导的已发表的研究做出了贡献。这篇文章今天可从Cell online获得，并于9月19日出版。。

“When we set out to build cutting-edge genetic medicines to address age-related diseases, we knew the ability to deliver nucleic acids safely and effectively to a broad array of cell types would be essential to our success,” said Matthew Scholz, chief executive officer, Oisín Biotechnologies. “We placed an early bet on the Entos FAST-PLV system because it has the potential to overcome the biodistribution, tolerability, and repeat-dosing limitations of other commonly used delivery systems.

Oisín Biotechnologies首席执行官马修·斯科尔茨（MatthewScholz）表示：“当我们着手构建尖端遗传药物以解决与年龄相关的疾病时，我们知道能够安全有效地将核酸输送到多种细胞类型对我们的成功至关重要。”。“我们对Entos FAST-PLV系统进行了早期押注，因为它有可能克服其他常用输送系统的生物分布，耐受性和重复给药限制。

The data published today in Cell validate that choice and provide important proof-of-principle for our follistatin gene therapy program. As we utilize the FAST-PLV system in our other ongoing development programs, the remarkable flexibility of the platform continues to support the broader potential of our genetic medicine approach to addressing age-related diseases.”.

今天发表在Cell上的数据证实了这一选择，并为我们的卵泡抑素基因治疗计划提供了重要的原理证明。随着我们在其他正在进行的开发计划中使用FAST-PLV系统，该平台的显着灵活性继续支持我们的遗传医学方法在解决与年龄有关的疾病方面的更广泛潜力。”。

The published data include results from studies conducted by Oisín scientists evaluating the impact of administering a single dose of FAST-PLV FST gene therapy in mice, over time. After 15 weeks, the mice administered with FST gene therapy had significantly greater grip strength and body weight increases than the control group.

公布的数据包括Oisín科学家进行的研究结果，该研究评估了随着时间的推移，在小鼠中施用单剂量FAST-PLV FST基因疗法的影响。15周后，给予FST基因治疗的小鼠比对照组具有显着更大的握力和体重增加。

At 34 weeks, the FST gene therapy mice showed significant increases in muscle size, especially in the hind limbs and throughout the torso, that correlated with a significant increase in cross-sectional muscle fiber area compared with the control group..

在34周时，FST基因治疗小鼠的肌肉大小显着增加，尤其是后肢和整个躯干，与对照组相比，横截肌纤维面积显着增加。。

“Muscle loss is associated with age-related frailty, which affects the mobility and quality of life for millions of elderly people,” said Henry Garcia, Ph.D., head of Aging R&D at Oisín. “With an aging population and the increasing use of GLP-1 class agonists to treat diabetes and obesity, there is a growing need for a therapy that can safely and effectively mitigate the side effect of muscle loss and, ideally, rebuild muscle.”.

Oisín衰老研发负责人亨利·加西亚博士说：“肌肉萎缩与年龄相关的虚弱有关，这会影响数百万老年人的活动能力和生活质量。”。“随着人口老龄化和越来越多地使用GLP-1类激动剂治疗糖尿病和肥胖症，人们越来越需要一种能够安全有效地减轻肌肉损失的副作用，理想情况下还能重建肌肉的疗法。”。

FAST-PLVs form the basis of the Entos Fusogenix™ PLV delivery platform. This technology is licensed to Oisin for the development of age-related disease applications. In July 2024, Oisín announced the first close of a $15 million Series A financing round, to advance its age-related disease therapy portfolio..

快速PLV构成了Entos Fusogenix™PLV交付平台的基础。该技术已获得Oisin的许可，用于开发与年龄相关的疾病应用。2024年7月，Oisín宣布第一轮1500万美元的a系列融资结束，以推进其与年龄有关的疾病治疗组合。。

About Oisín Biotechnologies

关于Oisín生物技术

Oisín is a privately held biotechnology company developing genetic medicines to address age-related diseases. Headquartered in Seattle, Washington, Oisín utilizes the Entos® Fusogenix™ PLV™ delivery platform to deliver DNA directly to cells throughout the body, addressing the damage and detrimental effects caused by the aging process itself.

Oisín是一家私营生物技术公司，开发基因药物以解决与年龄有关的疾病。总部位于华盛顿州西雅图的Oisín利用Entos®Fusogenix™PLV™传递平台将DNA直接传递给全身细胞，解决衰老过程本身造成的损害和有害影响。

The company’s first therapies focus on eliminating unwanted fat cells and building muscle mass. For more information, visit www.oisinbio.com or follow Oisín on X and LinkedIn..

该公司的第一批疗法专注于消除不需要的脂肪细胞和建立肌肉质量。有关更多信息，请访问www.oisinbio.com或关注X和LinkedIn上的Oisín。。

About Entos Pharmaceuticals Inc.

关于Entos Pharmaceuticals Inc。

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and re-dosable nucleic acid delivery technologies. Since its inception in 2016, Entos® has been dedicated to advancing next-generation genetic medicines using our proprietary FusogenixTM PLVTM drug delivery system.

遗传医学面临着一个新的现实，随着安全，有效和可重复给药的核酸递送技术的出现，这将迎来一个新的现实。自2016年成立以来，Entos®一直致力于使用我们专有的FusogenixTM PLVTM药物输送系统推进下一代遗传药物。

The Fusogenix PLV platform is formulated with FAST proteins to enable the delivery of nucleic acid to target cells through direct fusion. Entos is pioneering the development of life-changing medicines for patients and has partnered with global companies, such as Eli Lilly, to accelerate and expand the impact of our platform.

Fusogenix PLV平台由快速蛋白质配制而成，可通过直接融合将核酸递送至靶细胞。Entos率先为患者开发改变生命的药物，并与礼来（Eli Lilly）等全球公司合作，以加速和扩大我们平台的影响。

Entos Pharmaceuticals Inc. is headquartered in Edmonton, Canada, with its wholly owned U.S. and U.K. subsidiaries based in San Diego, California and London, United Kingdom, respectively. For more information, visit www.entospharma.com, or follow Entos on LinkedIn..

Entos Pharmaceuticals Inc.总部位于加拿大埃德蒙顿，其全资拥有的美国和英国子公司分别位于加利福尼亚州圣地亚哥和英国伦敦。有关更多信息，请访问www.entospharma.com，或在LinkedIn上关注Entos。。

Entos® word mark and design logo, FusogenixTM and PLVTM are registered trademarks of Entos Pharmaceuticals Inc. All other trademarks and registered trademarks are the property of their respective owners.

Entos®文字标记和设计徽标、FusogenixTM和PLVTM是Entos Pharmaceuticals Inc.的注册商标。所有其他商标和注册商标均为其各自所有者的财产。